Eribulin mesylate: A new therapeutic option for metastatic breast cancer

S. Aditya
{"title":"Eribulin mesylate: A new therapeutic option for metastatic breast cancer","authors":"S. Aditya","doi":"10.4103/2278-960X.112571","DOIUrl":null,"url":null,"abstract":"More than a million women are diagnosed with breast cancer annually worldwide. Death from breast cancer is usually a result of chemotherapy‑resistant metastatic disease. Eribulin mesylate is a recent addition to the therapeutic armamentarium for treating locally advanced or metastatic breast cancer (MBC) in patients who have received at least two prior chemotherapy regimens for late‑stage disease. This synthetic analog, derived from a marine sponge macrolide halichondrin B, inhibits microtubule stability by blocking microtubule growth without affecting microtubule shortening. The US Food and Drug Administration has approved eribulin mesylate as a third‑line treatment for MBC refractory to anthracyclines and taxanes based on a Phase III clinical trial showing significantly increased overall survival compared to treatment of investigator’s. Asthenia, fatigue, neutropenia, alopecia, nausea, anorexia, and neuropathy are the most frequent adverse effects associated with this drug. The aim of this review was to highlight the importance of this drug in the management of breast cancer. Medline, Excerpta Medica database, cochrane database, medscape, Elsevier Scopus, and clinicaltrials.gov were searched using terms “eribulin,” “E7389,” “halichondrin,” “metastatic breast cancer.” Journal articles published from 2007 to 2012 discussing pharmacology and/or clinical trials were screened. The development of this microtubule inhibitor helps to address the need for additional effective regimens for patients progressing after standard treatment with anthracycline‑ and taxane‑containing regimens.","PeriodicalId":356195,"journal":{"name":"Journal of Basic and Clinical Reproductive Sciences","volume":"28 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Basic and Clinical Reproductive Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/2278-960X.112571","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

More than a million women are diagnosed with breast cancer annually worldwide. Death from breast cancer is usually a result of chemotherapy‑resistant metastatic disease. Eribulin mesylate is a recent addition to the therapeutic armamentarium for treating locally advanced or metastatic breast cancer (MBC) in patients who have received at least two prior chemotherapy regimens for late‑stage disease. This synthetic analog, derived from a marine sponge macrolide halichondrin B, inhibits microtubule stability by blocking microtubule growth without affecting microtubule shortening. The US Food and Drug Administration has approved eribulin mesylate as a third‑line treatment for MBC refractory to anthracyclines and taxanes based on a Phase III clinical trial showing significantly increased overall survival compared to treatment of investigator’s. Asthenia, fatigue, neutropenia, alopecia, nausea, anorexia, and neuropathy are the most frequent adverse effects associated with this drug. The aim of this review was to highlight the importance of this drug in the management of breast cancer. Medline, Excerpta Medica database, cochrane database, medscape, Elsevier Scopus, and clinicaltrials.gov were searched using terms “eribulin,” “E7389,” “halichondrin,” “metastatic breast cancer.” Journal articles published from 2007 to 2012 discussing pharmacology and/or clinical trials were screened. The development of this microtubule inhibitor helps to address the need for additional effective regimens for patients progressing after standard treatment with anthracycline‑ and taxane‑containing regimens.
甲磺酸埃瑞布林:转移性乳腺癌的新治疗选择
全世界每年有100多万妇女被诊断患有乳腺癌。乳腺癌的死亡通常是化疗或耐药转移性疾病的结果。甲磺酸埃立布林是最近增加的一种治疗方法,用于治疗局部晚期或转移性乳腺癌(MBC)患者,这些患者之前至少接受过两次晚期疾病的化疗方案。这种合成类似物来源于海绵大环内酯软海绵素B,通过阻断微管生长而不影响微管缩短来抑制微管稳定性。基于一项III期临床试验,美国食品和药物管理局(fda)已批准甲磺酸埃立布林作为三线治疗蒽环类药物和紫杉烷类药物难治MBC的药物,该临床试验显示,与研究者的治疗相比,该药物的总生存率显著提高。虚弱、疲劳、中性粒细胞减少、脱发、恶心、厌食和神经病变是与该药相关的最常见的不良反应。这篇综述的目的是强调这种药物在乳腺癌治疗中的重要性。Medline、摘录医学数据库、cochrane数据库、medscape、爱思唯尔Scopus和clinicaltrials.gov使用“eribulin”、“E7389”、“halichondrin”、“转移性乳腺癌”进行搜索。筛选2007年至2012年发表的讨论药理学和/或临床试验的期刊文章。这种微管抑制剂的开发有助于解决在使用含有蒽环类药物和紫杉烷的标准治疗方案后进展的患者对其他有效方案的需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信